MicroRNA-765 is pregulated in multiple myeloma and serves an oncogenic role by directly targeting SOX6

Area of Science:

• Molecular Biology
• Oncology
• Biochemistry

Background:

• MicroRNAs (miRNAs) play crucial roles in cancer development and progression.
• Multiple myeloma (MM) is a hematological malignancy with complex pathogenesis.
• The specific role of microRNA-765 (miR-765) in MM remains largely uncharacterized.

Purpose of the Study:

• To investigate the expression pattern, biological functions, and underlying mechanisms of miR-765 in multiple myeloma.
• To identify potential therapeutic targets for MM based on miR-765's role.

Main Methods:

• Quantification of plasma and cellular miR-765 levels in MM patients and cell lines.
• Functional assays assessing the impact of miR-765 modulation on MM cell proliferation and apoptosis.
• Bioinformatics analysis to predict miR-765 targets, followed by experimental validation (luciferase reporter assay, RT-qPCR, Western blot).
• Investigation of the relationship between miR-765 and its target gene, SOX6, in MM.

Main Results:

• Plasma miR-765 levels were significantly increased in MM patients and cell lines.
• Downregulation of miR-765 in MM cells reduced proliferation and induced apoptosis.
• SRY-Box 6 (SOX6) was identified and validated as a direct target of miR-765.
• Plasma SOX6 was downregulated in MM patients, inversely correlated with miR-765 expression.
• SOX6 knockdown reversed the anti-proliferative and pro-apoptotic effects of miR-765 underexpression.

Conclusions:

• miR-765 functions as an oncogene in multiple myeloma progression.
• miR-765 promotes MM by directly targeting and downregulating SOX6 expression.
• miR-765 represents a potential therapeutic target for the prevention and treatment of MM.